LIFE aTyr Pharma, Inc.

2.50
+0  (0%)
Previous Close 2.50
Open 2.50
Price To book 0.80
Market Cap 59.30M
Shares 23,718,000
Volume 28,828
Short Ratio 4.41
Av. Daily Volume 172,984

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 1H 2017.
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Data from first four patients released December 13, 2016.
Resolaris
Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B

Latest News

  1. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure
  2. Roberts recuses from patent case after discovering conflict
  3. Roberts recuses from patent case after discovering conflict
  4. Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
  5. Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?
  6. aTyr Pharma downgraded by JP Morgan
  7. aTyr Pharma Drops on Clinical Update
  8. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events
  9. aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials
  10. aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference
  11. aTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
  12. ATYR PHARMA INC Financials
  13. aTyr Pharma Enters into $20 Million Credit Facility
  14. ATYR PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive
  15. aTyr Pharma Enters into $20 Million Credit Facility
  16. aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session
  17. aTyr Pharma Announces Third Quarter 2016 Operating Results
  18. ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  19. aTyr Pharma Announces Third Quarter 2016 Operating Results
  20. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure